Viatris launches rapid self-test to detect antibodies developed after Covid-19 jab

American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations.

The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of neutralising antibodies after vaccination.

The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired.The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20.

After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine.

It recommended that the test be performed at least 14 days after completing the vaccination cycle.

Leave a Reply